Saudi Journal of Otorhinolaryngology Head and Neck Surgery
Abstract Acute otitis media (AOM) represents a prevalent infection in children globally, leading to considerable morbidity and imposing a substantial burden on healthcare systems. Prompt and precise diagnosis is critical to reducing complications, such as tympanic membrane perforation, hearing impairment, and excessive antibiotic prescribing. Advances in artificial intelligence (AI), particularly deep learning, have created opportunities to enhance diagnostic accuracy and broaden access to care, especially in low-resource settings. This systematic review and meta-analysis aimed to evaluate the diagnostic performance of AI-based systems for detecting AOM compared with conventional clinical diagnosis and to analyze their accuracy relative to human clinicians across different model architectures and diagnostic methods. Following PRISMA-DTA standards and PROSPERO registration, systematic searches were conducted in PubMed, Web of Science, and IEEE Xplore up to July 30, 2025. Eligible studies included human participants with suspected AOM, employed AI-driven diagnostic approaches, and used a clinical reference standard. The Quality Assessment of Diagnostic Accuracy Studies-2 tool assessed bias, and pooled sensitivity and specificity were estimated using a bivariate random-effects model. Nine studies published between 2020 and 2025 met the inclusion criteria. The pooled sensitivity and specificity were 91% (95% confidence interval [CI]: 77%–97%) and 99% (95% CI: 94%–100%), respectively. AI models overall matched or outperformed general practitioners and pediatricians, approaching otolaryngologist-level accuracy. AI-based tools have the potential to improve AOM detection, mitigate inequalities in healthcare access, and promote more effective diagnosis, particularly in underserved regions.
Protracted bacterial bronchitis (PBB) is a treatable cause of chronic wet cough in children but is frequently missed.Unrecognized children often cycle through repeat asthma treatment, short antibiotic courses that do not address the infection, or open-ended reassurance without further evaluation.This review summarizes the clinical presentation, diagnostic criteria, differential diagnosis, treatment, and follow-up of PBB in children.We conducted a targeted narrative review (PubMed, through September 2026) of clinical trials, longitudinal studies, systematic reviews, and professional-society guidance, distinguishing evidence for antibiotic treatment from limited observational evidence linking recurrent PBB to bronchiectasis.Clinicians should suspect PBB in a child with a daily wet cough lasting more than four weeks and no findings indicating another cause.Resolution after an appropriate antibiotic course supports the diagnosis.Amoxicillinclavulanate remains the usual first-line treatment, typically for two weeks initially, with reassessment and selective extension to four weeks if the child has not cleared.Further investigation is warranted when symptoms persist despite adequate treatment, recurrence is frequent, or specific warning signs appear.In an otherwise typical, treatment-responsive case, bronchoscopy and chest computed tomography (CT) are not routine first steps.Management hinges on recognizing the wet-cough phenotype, giving an adequate therapeutic trial, confirming resolution, and investigating promptly when treatment fails.Antibiotics appear to improve cough resolution, but this rests on a small number of trials with limited certainty, and evidence that treatment itself prevents bronchiectasis remains thin.
Tavapadon is an oral, once-daily, non-catechol partial agonist selective for the D1 and D5 dopamine receptors and represents a mechanistically distinct option currently under clinical investigation for Parkinson disease (PD). This narrative review critically evaluates the biological rationale for D1/D5 receptor targeting, the pharmacological and preclinical development of tavapadon, and the accumulating phase 1–3 clinical evidence for its use as monotherapy in early PD and as adjunctive therapy in patients with motor fluctuations, while highlighting remaining evidence gaps and methodological limitations. A non-systematic literature search of PubMed/MEDLINE, Embase, ClinicalTrials.gov , and Scopus (through May 2026) was performed to identify representative and pivotal randomized controlled trials, pharmacokinetic/pharmacodynamic studies, and mechanistic preclinical investigations relevant to tavapadon and D1/D5 receptor agonism; this narrative approach was not intended to be exhaustive or fully reproducible in the manner of a systematic review. Mechanistically, selective stimulation of the direct striatal pathway together with submaximal intrinsic efficacy at the D1 receptor has been proposed, as a mechanistic hypothesis rather than a demonstrated clinical mechanism, to preserve antiparkinsonian benefit while limiting the receptor-signaling intensity implicated in levodopa-induced dyskinesia. In the phase 2 PARKWAY-II study and the now fully published phase 3 TEMPO-1 and TEMPO-2 trials, fixed- and flexible-dose tavapadon produced clinically meaningful improvements in MDS-UPDRS motor scores compared with placebo in early PD, and in the phase 3 TEMPO-3 trial, adjunctive tavapadon significantly increased daily good ON time and reduced OFF time in levodopa-treated patients with motor fluctuations; efficacy in all trials has been demonstrated only against placebo, with no head-to-head data against levodopa or other dopamine agonists. Adverse events were more frequent with tavapadon than placebo (approximately 72–76% versus 55% across TEMPO-2 and TEMPO-3), with nausea, headache, and dizziness the most common; no excess signal of impulse-control disorders relative to placebo was detected over the available 26–27-week controlled treatment period, and no clinically significant QTc prolongation was observed. The 58-week open-label TEMPO-4 extension, now reported in a peer-reviewed AAN abstract publication in Neurology alongside earlier interim conference data, suggests sustained benefit and a stable long-term levodopa requirement, but lacks a randomized control and cannot yet establish long-term safety superiority over existing agents. Tavapadon is a mechanistically novel candidate with preliminary evidence of efficacy; its ultimate clinical utility will depend on head-to-head trials and long-term safety data.
Abstract Background Melatonin is an endogenous hormone that regulates the body’s sleep-wake cycles. Due to several clinical trials, it is currently used as an exogenous supplement in pediatric patients who suffer from sleep-onset insomnia (SOI). Consequently, this systematic review and meta-analysis aimed to assess the evidence for the clinical efficacy of melatonin for SOI in children aged 6–12. Methods This systematic review and meta-analysis evaluated the efficacy and safety of Melatonin for sleep-onset insomnia in children aged 6–12 by conducting literature searches in PubMed (97), Google Scholar (111), OVID (33), and Web of Science (156) databases. We performed statistical tests using RevMan for meta-analysis. Heterogeneity was evaluated using the I2 statistic. To maintain the validity of the studies, each included study was assessed by the Cochrane Collaboration Risk of Bias (ROB) tool. The outcomes investigated were sleep onset time (SOT), sleep onset latency (SOL), total sleep time (TST), all-cause dropout rates, and adverse-event dropout rates. Results Three hundred ninety-eight records were identified, and 10 randomized clinical trials met the inclusion criteria. The results demonstrated that melatonin treatment group was associated with an earlier sleep onset time compared with placebo with a mean difference (MD) of -0.48 h (approximately 29 min earlier) (95% confidence interval [CI]: -0.93 to -0.02 h, p = 0.04). The heterogeneity between studies was moderate (I2 = 63%). On the other hand, it was noted that there has been noticed there was a remarkable reduction in sleep onset latency with melatonin compared to placebo, with an MD of -0.38 (95% CI: -0.57 to -0.20, p < 0.0001), with high heterogeneity (I2 = 82%). Conclusion Our study confirmed that melatonin has a marked effect regarding Sleep-onset insomnia in childhood. Therefore, we found there was a statistical and clinical improvement in sleep parameters such as sleep onset time (SOT) and total sleep time (TST) which demonstrated the safety and efficacy of melatonin. However, long-term efficacy and safety need to be addressed, especially in the pediatric population.
American Journal of Pediatrics · مجلد 12 (3) · 87-102
Background: Parapneumonic effusion (PPE) and empyema remain serious complications of childhood pneumonia associated with significant morbidity despite advances in antimicrobial therapy and surgical techniques. Accurate disease staging and timely stage-directed intervention are fundamental to optimal outcomes. Objective: To provide a current, evidence-based synthesis of the definition, etiology, diagnosis, and management of complicated pneumonia in children, with particular focus on areas of ongoing clinical controversy. Methods: A narrative review incorporating randomized controlled trials, systematic reviews, meta-analyses, Cochrane reviews, and international clinical guidelines published between 2016 and 2026 was conducted. PubMed was searched through May 2026 using terms including pneumonia, complicated pneumonia, parapneumonic effusion, empyema, VATS, fibrinolysis, decortication, and pediatric. Results: Chest radiography remains the initial imaging modality for suspected complicated pneumonia, with lateral decubitus views needed to assess pleural fluid mobility. However, chest ultrasonography is the preferred imaging modality for evaluating parapneumonic effusions and empyema because of its superior diagnostic accuracy, ability to characterize pleural collections, and absence of ionizing radiation. Management is stage-dependent, combining targeted antibiotic therapy with procedural intervention when indicated. Image-guided pigtail catheter drainage with intrapleural fibrinolytic therapy is effective for most patients. VATS demonstrates particular utility during the fibrinopurulent stage. No single fibrinolytic agent has demonstrated clear superiority; however, tissue plasminogen activator is most widely employed. Open decortication remains reserved for refractory or advanced-stage disease. Conclusion: Early diagnosis, appropriate antibiotics, and prompt intervention or surgery are all important for optimal care. The optimal outcomes require a multidisciplinary, individualized, stage-directed approach. Interventional radiology is appropriate for single loculations, while early VATS is favored for thick pleural rind or multiple loculations. Further high-quality prospective research is needed to establish definitive treatment algorithms.
Objective: To evaluate and compare the safety and effectiveness of antipsychotic medications for the treatment of hiccups, thereby guiding clinicians toward evidence-based treatment guidelines. Hiccups are often benign and self-limiting; however, they can become persistent and intractable, adversely affecting the quality of life. Antipsychotics have been identified as a therapeutic option for the management of hiccups; however, the available evidence supporting their safety and efficacy has not been synthesized. Methods: This review utilized the revised Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. The Cochrane Risk of Bias Assessment Tool was modified to evaluate the quality of the selected studies. The search strategy included terms related to or describing hiccups and antipsychotics. Research articles in English published between 1974 and March 2024 were searched in different databases. Duplicates and eligibility criteria were used to screen articles. Results: A search of Medline, Scopus, and Web of Science yielded 1537 articles, of which 1042 were retained after removing duplicates, and 16 met the inclusion criteria. The studies that met the inclusion criteria were all case reports, case series, or retrospective studies, with no randomized trials. A few antipsychotics have been shown to totally or partially alleviate hiccups. Nine studies reported that hiccups were completely resolved in patients treated with 10-25 mg oral and intramuscular chlorpromazine, 1-2 mg oral and intramuscular haloperidol, 2.5-10 mg oral olanzapine, 25-150 mg tetrabenazine, and 3 mg oral risperidone. Adverse events were documented in 7 of the studies. Conclusion: Chlorpromazine and olanzapine are effective antipsychotics for hiccup treatment. However, more evidence-based studies and controlled clinical trials are needed to confirm the efficacy and minimize the side effects. PROSPERO registration: (CRD42024511626).
Background: Plaque psoriasis, which is a chronic immune-mediated inflammatory skin condition, significantly reduces patients' quality of life. The cytokine interleukin-23 (IL-23) is a pivotal factor in the development of psoriasis, and icotrokinra is a new oral IL-23 receptor antagonist that has shown potential effectiveness in clinical trials. The main goal of this systematic review and meta-analysis was to assess the effectiveness and safety of icotrokinra in adults and adolescents with moderate-to-severe plaque-type psoriasis. Methods: A comprehensive literature search in PubMed, ScienceDirect, and the Cochrane Library, conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) standards, identified randomized controlled trials that evaluated daily oral icotrokinra 200 mg versus placebo. The primary outcomes were Psoriasis Area and Severity Index (PASI) 90, Investigator's Global Assessment (IGA) 0/1, and adverse events (AEs) at 16 weeks. Risk ratios with 95% confidence intervals were summed up through a random-effects model. Results: A total of five randomized controlled trials involving 2,755 participants were included. Icotrokinra showed a significant increase in PASI 90, IGA 0/1, IGA 0, and Psoriasis Symptoms and Signs Diary 0 responses compared to placebo. The overall frequency of AEs was similar in both groups, but the rate of treatment discontinuation due to AEs was lower with icotrokinra. Conclusions: Icotrokinra is an effective and well-tolerated oral treatment for moderate-to-severe plaque psoriasis with considerable clinical and patient-reported benefits.
Learning disabilities (LD) present substantial challenges for both affected individuals and society, often going under-recognized, leading to delays in diagnosis and inadequate interventions. These conditions are complex and caused by a mix of genetics, environment, and brain function. This can affect the sensory and mental information during processing, making learning more difficult. A systematic review of 19 selected studies was conducted using databases such as PubMed, Embase, Cochrane Library, and Web of Science. Studies were evaluated for risk of bias, and findings were synthesized to offer an integrated understanding of the etiology, pathophysiology, diagnostic complexities, and treatment strategies associated with LD. Key genetic and environmental risk factors were identified, and diagnostic challenges were explored, with an emphasis on the role of neurocognitive assessments and educational tools for accurate identification. The effectiveness of different treatments, such as educational programs, cognitive therapy, and novel technologies, was also assessed in terms of how well they help improve learning outcomes. The information processing theory was examined in depth, illustrating how disruptions in the processing of sensory and cognitive stimuli contribute to the learning difficulties observed in LD. The review also emphasizes the need for a team effort, bringing together parents, teachers, healthcare workers, and communities. This might provide vital support for people with LD. Advances in educational technology and cognitive training offer promising avenues for improving information processing and, consequently, educational outcomes. A holistic approach to diagnosis and intervention is essential for optimizing the quality of life and educational success of individuals with LD.
Advanced Health Science and Technology Journal · مجلد 1 (1) · 9-22
Abstract Neurodegenerative diseases (NDDs) pose a significant global health challenge, causing progressive neuronal loss and debilitating impairments. While current treatments offer only symptomatic relief, small interfering RNAs (siRNAs) have emerged as a promising therapeutic modality. This systematic review analyzed the literature (2000-2025) from different databases on siRNA therapy for NDDs, focusing on mechanisms, delivery approaches, therapeutic efficacy, and safety profiles to provide an integrated, evidence-based synthesis. The siRNA precise sequence specificity allows them to silence disease-related genes, addressing the root causes of these disorders. This review examines the fundamental biology of siRNAs, including advancements in their design, chemical modification, and innovative strategies to overcome the blood–brain barrier (BBB) for central nervous system delivery. We detail siRNA-based therapeutic strategies for major NDDs – Alzheimer’s disease, Parkinson’s disease, Huntington’s disease, and amyotrophic lateral sclerosis – highlighting the transition from preclinical successes to clinical trials. Despite challenges in delivery and immunogenicity, the precision of siRNA-mediated gene silencing positions this technology at the forefront of efforts to develop disease-modifying treatments, paving the way for a new era of personalized neurotherapeutics.
Background: Medication turnaround time (TAT) is a critical metric for evaluating the efficiency and safety of hospital pharmacy operations. Optimizing TAT is essential to ensure patient safety, reduce medication errors, enhance workflow efficiency, enhance resource utilization and enhance both the continuity of care and patient satisfaction. Aim: To discuss the important of TAT, factors influencing medication TAT and provide evidence-based recommendations to optimize medication delivery thereby improve patient care. Methods: A comprehensive search of PubMed, Google Scholar, and ScienceDirect was conducted up to June 15, 2025. Eligible studies included if they were conducted in inpatient settings and reported medication TAT as outcome. Outpatient studies and those without relevant data were excluded. Data on study characteristics, interventions, and outcomes were extracted and summarized narratively; no meta-analysis was performed due to the heterogeneity of the studies. Results: Analysis identified several determinants of prolonged TAT included inefficient health IT systems, inadequate communication, staffing limitations, and inconsistent workflows. Effective interventions encompassed automation, workflow redesign, staff role optimization, and process standardization. These strategies consistently reduced TAT, with reported improvements of 10% to over 50%. Conclusion: TAT is a fundamental indicator to measure hospital pharmacy performance and improve patient outcomes. Addressing the barriers through evidence-based strategies can significantly streamline the medication use process. Optimizing medication TAT requires a multifaceted approach that include integrates technology, standardized workflows, and improve human factors. Evidence suggests these approaches not only enhance operational efficiency but also reduce errors, strengthen regulatory compliance, and ultimately improve patient safety as well as satisfaction.
Saudi Journal for Health Sciences · مجلد 14 (2) · 139-149
ABSTRACT Familial hypercholesterolemia (FH) is a genetic disorder characterized by high levels of low-density lipoprotein cholesterol (LDL-C). If left untreated during childhood, FH can result in early-onset cardiovascular disease (CVD). Statin treatment can reduce the risk of early-onset atherosclerotic CVD associated with FH. For this atherosclerosis-related condition, early therapy is essential to avoid major cardiac damage. The systematic review was performed following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, with a comprehensive electronic search carried out across the Web of Science, EBSCO, and PubMed databases. The search terms used included combinations of keywords and medical subject headings relevant to the study objective. The search string was: statins OR familial hypercholesterolemia OR children OR adolescents OR LDL cholesterol OR cholesterol-lowering therapy OR pediatric hypercholesterolemia OR statin efficacy OR statin safety OR long-term outcomes OR cardiovascular risk OR lipid management OR growth and development. This study included 18 articles with a total sample size of 2811 participants. The findings revealed that in the group treated with statins, total cholesterol (TC), LDL-C, and triglycerides decreased by MD = −31.16 (95% confidence interval [CI]: −42.12, −20.19), MD = −14.31 (95% CI: −20.91, −7.70), and MD = −5.53 (95% CI: −6.35, −4.72), respectively. Although there was an increase in high-density lipoprotein cholesterol (HDL-C) by MD = 0.29 (95% CI: −0.45, 1.03), but the difference was not statistically significant ( P = 0.45). Statins significantly reduce TC, LDL-C, and TG in children and adolescents with FH while increasing HDL-C levels. On the other hand, this study found statin to be efficient in treating children and adolescents with familial hypercholesterolemia. Similarly, the study did not find any safety issues with statin medication. However, this study suggests future studies focusing on randomized control trials only, in order to ascertain the results obtained in this study.
statinsfamilial hypercholesterolemiapediatric hypercholesterolemiachildren and adolescents
Parkinson's disease (PD) is a progressive neurodegenerative disorder characterized by motor and non-motor symptoms that profoundly impact patients' quality of life. While pharmacological therapies such as levodopa remain the mainstay of treatment, their long-term use is often limited by motor complications. Device-based interventions, including deep brain stimulation (DBS) and continuous dopaminergic infusions, have emerged as alternatives, promising sustained symptomatic control and reduced medication-related side effects. This systematic review and meta-analysis evaluate the comparative efficacy, safety, and cost-effectiveness of device-based interventions versus pharmacological therapies in the management of advanced PD. A comprehensive search was conducted across multiple databases to identify randomized controlled trials, observational studies, and systematic reviews. Primary outcomes included motor function improvement, quality of life, and adverse events. Meta-analyses were performed, and subgroup analyses explored the effectiveness of specific interventions. Device-based interventions demonstrated superior efficacy over pharmacological therapies, with a pooled effect size (Cohen's d) of 1.12 (95% confidence interval (CI): 0.94-1.29) for motor symptom control and quality of life improvements. Subgroup analyses showed DBS and levodopa-carbidopa intestinal gel to be particularly effective, with levodopa-carbidopa intestinal gel showing a Cohen's d of 1.25 (95% CI: 0.91-1.58). Device-based therapies also reduced medication dosages and associated motor complications. Sensitivity analyses confirmed the robustness of these findings, and no significant publication bias was detected. However, gaps remain in understanding the long-term outcomes and cost-effectiveness of these interventions. Device-based interventions, especially DBS and levodopa-carbidopa intestinal gel, offer superior symptom control and quality of life improvements compared to traditional pharmacological therapies in advanced PD. These findings support the integration of device-based therapies into personalized treatment strategies. Further research is needed to explore long-term outcomes and establish standardized guidelines for their implementation in clinical practice.
Saudi Medical Horizons Journal · مجلد 4 (3) · 169-180
Patients diagnosed with systemic lupus erythematosus (SLE) face a much greater risk of morbidity and mortality from cardiovascular disease (CVD) when compared to the overall population. Despite numerous case reports and literature reviews delving into this connection, there are only a handful of systematic reviews that have specifically concentrated on this link. As a result, the objective of this systematic review is to assess the depth of the relationship between SLE and cardiovascular diseases. An extensive search was conducted primarily using PubMed and following PRISMA criteria. The search targeted English-language studies investigating the link between SLE and cardiovascular diseases. Clear inclusion and exclusion criteria were set to guarantee the quality and relevance of the evaluated research. The research encompassed a broad spectrum of studies from various global regions, with no particular emphasis on any specific gender or age. An evident trend revealed a significant proportion of SLE patients experiencing cardiovascular conditions. According to the findings of our investigation, in general, it was discovered that patients with SLE have a greater chance of developing CVD. It is essential to conduct additional research on the connection between identifiable SLE-specific risk factors that can be modified and the likelihood of developing CVD in order to bolster the creation of preventative and treatment measures.
Background/ objectives: The frequency of related comorbidities, all-cause mortality, and societal costs are all on the rise, and so is the burden of gout and hyperuricemia globally. This systematic review aims to investigate the recently published literature on the prevalence and risk factors of gout and hyperuricemia. PubMed, Web of S Methods: cience, Science Direct, and Cochrane Library were systematically searched to include the relevant literature. Rayyan QRCI was used throughout this systematic approach. Results: Our results included eleven studies with a total of 204,759,079 patients diagnosed with gout and/ or hyperuricemia. The reported total prevalence of hyperuricemia was 40,169,245 (19.6%), and the prevalence of gout was 6,192,105 (3.02%). The included studies recorded a rising incidence of gout and hyperuricemia. Gout is thus an increasing problem over the world, and to addr Conclusion: ess and improve widespread poor care, international cooperation efforts are needed. Hyperuricemia and gout affected males more than females. Older age, obesity, male gender, less activity, a diet heavy in purines, and lower educational levels all had an impact on blood UA concentration. These are high-risk populations that need to have their UA levels regularly checked.
The emergence of blockchain know-how currently presents the opportunity for the health sector to adopt such technologies in electronic health records. Blockchain assists in maintaining and sharing the relevant medical records of the patient with the relevant group of healthcare providers and the hospital. Numerous specific applications include traceability of drug and patient monitoring or Electronic Health Records (EHR). While Blockchain assists in maintaining and sharing the relevant medical records of the patient with the relevant group of healthcare providers and the hospital, it is important to note that the moral consciousness of the healthcare professionals is the main guide of the moral consciousness is ethics. This paper presents an overview of the application of blockchain in the healthcare and medical sector, highlighting the specific challenges and concerns. The study adopted a systematic review of secondary literature in answering the research question.
blockchainhealth careelectronic health recordsdecentralization (distributed systems)